- Email: [email protected]
Refractory Indolent B-Cell Lymphoma and Mantle Cell Lymphoma
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.46
Poster Session (Poster presentations categorized by each organ) P1
22
1
Toshiki Yamada1, Nobuhiko Nakamura2, Jun-ichi Kitagawa2, Nobuhiro Kanemura2, Naoe Goto2, Senji Kasahara3, Hideko Goto3, Kenji Fukuno4, Takeshi Hara2, Hisashi Tsurumi2 1 Department of Hematology, Gifu Prefectural General Medical Center 2 1st Dep. Int. Med., Gifu Univ. Sch. Med 3 Department of Hematology, Gifu Municipal Hospital 4 Department of Hematology, Gifu Red Cross Hospital
abstracts
Background: Bendamustine (Ben) and combinations of Ben/rituximab(R) therapies have shown high efficacy in relapsed/refractory indolent B-cell non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). No data exist about Ben retreatment after relapse, concerning efficacy and toxicity in these patients ( pts) population.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v85/2240484 by guest on 25 October 2019
RETREATMENT WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA
Patients and methods: Six pts (3 with follicular lymphoma, 1 lymphoplasmacytic lymphoma, 2 MCL) who had previously successfully been treated with first Ben and maintained its efficacy for over 6 months were retreated with Ben between December 2010 and November 2013. The median age was 72 years (61-75) and the ratio of gender was 2 males and 4 females. Pts received Ben at 90-120mg/m2 on day 1 and 2 in a 21-28 days cycle for up to 6 cycles. R (375mg/m2) was added on day 1 in 5 pts. Prophylactic acyclovir and trimethoprim-sulfamethoxazole (ST) were used. Granulocyte colony-stimulating factor (G-CSF) was administered in case of severe neutropenia. The observation duration was 30 months (18-33) from the first treatment and 6 months (2-11) from retreatment. Results: The number of previous regimens was 2 (1-5). An overall response rate of 83.3% (5 in 6 pts) (33.3% complete response rate (CR) and 50% partial response) was observed by 5 cycles (2-6) of Ben. Those 5 patients previously obtained CR by the first Ben. Another 1 pt who had previously obtained stable disease (SD) by the first Ben again got SD by retreatment of Ben. Response duration was 6 months (4-10). Grade 3 or 4 reversible hematologic toxicities were observed. Severe non-hematologic adverse events were not observed. Although cytomegalovirus (CMV) antigenemia was observed in 3 pts, the treatment of CMV was not required. Conclusion: Our data suggest high activity and good tolerance of Ben retreatment (and R) in pts with relapsed/refractory lymphoma despite previous Ben treatment. In view of this, prospective studies should be considered to establish efficacy and safety of Ben retreatment.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P1
22
1
Toshiki Yamada1, Nobuhiko Nakamura2, Jun-ichi Kitagawa2, Nobuhiro Kanemura2, Naoe Goto2, Senji Kasahara3, Hideko Goto3, Kenji Fukuno4, Takeshi Hara2, Hisashi Tsurumi2 1 Department of Hematology, Gifu Prefectural General Medical Center 2 1st Dep. Int. Med., Gifu Univ. Sch. Med 3 Department of Hematology, Gifu Municipal Hospital 4 Department of Hematology, Gifu Red Cross Hospital
abstracts
Background: Bendamustine (Ben) and combinations of Ben/rituximab(R) therapies have shown high efficacy in relapsed/refractory indolent B-cell non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). No data exist about Ben retreatment after relapse, concerning efficacy and toxicity in these patients ( pts) population.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v85/2240484 by guest on 25 October 2019
RETREATMENT WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA
Patients and methods: Six pts (3 with follicular lymphoma, 1 lymphoplasmacytic lymphoma, 2 MCL) who had previously successfully been treated with first Ben and maintained its efficacy for over 6 months were retreated with Ben between December 2010 and November 2013. The median age was 72 years (61-75) and the ratio of gender was 2 males and 4 females. Pts received Ben at 90-120mg/m2 on day 1 and 2 in a 21-28 days cycle for up to 6 cycles. R (375mg/m2) was added on day 1 in 5 pts. Prophylactic acyclovir and trimethoprim-sulfamethoxazole (ST) were used. Granulocyte colony-stimulating factor (G-CSF) was administered in case of severe neutropenia. The observation duration was 30 months (18-33) from the first treatment and 6 months (2-11) from retreatment. Results: The number of previous regimens was 2 (1-5). An overall response rate of 83.3% (5 in 6 pts) (33.3% complete response rate (CR) and 50% partial response) was observed by 5 cycles (2-6) of Ben. Those 5 patients previously obtained CR by the first Ben. Another 1 pt who had previously obtained stable disease (SD) by the first Ben again got SD by retreatment of Ben. Response duration was 6 months (4-10). Grade 3 or 4 reversible hematologic toxicities were observed. Severe non-hematologic adverse events were not observed. Although cytomegalovirus (CMV) antigenemia was observed in 3 pts, the treatment of CMV was not required. Conclusion: Our data suggest high activity and good tolerance of Ben retreatment (and R) in pts with relapsed/refractory lymphoma despite previous Ben treatment. In view of this, prospective studies should be considered to establish efficacy and safety of Ben retreatment.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].